135 related articles for article (PubMed ID: 9020948)
1. [Bropirimine (U-54461S) early phase II clinical studies--to investigate the efficacy and safety of bropirimine treatment on various malignant tumors (urological, hematologic, and dermal cancers)].
Furue H; Machida T; Masaoka T; Ikeda S
Gan To Kagaku Ryoho; 1997 Jan; 24(1):67-75. PubMed ID: 9020948
[TBL] [Abstract][Full Text] [Related]
2. [Bropirimine (U-54461S) late phase II clinical study for carcinoma in situ of the bladder. Japan Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1997 Jan; 24(1):77-85. PubMed ID: 9020949
[TBL] [Abstract][Full Text] [Related]
3. [Bropirimine (U-54461S) phase I clinical studies].
Furue H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1941-9. PubMed ID: 8978802
[TBL] [Abstract][Full Text] [Related]
4. [TUT-7 early phase II clinical study for various solid tumors and hematologic malignancies].
Taguchi T; Wakui A; Niitani H; Furue H; Majima H; Ota K; Ariyoshi H; Hattori T; Sugimachi K; Tsukagoshi S
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1253-61. PubMed ID: 9279344
[TBL] [Abstract][Full Text] [Related]
5. [Late phase II clinical study for bropirimine (U-54461S) in situ carcinoma of the bladder: follow-up investigation. Bropirimine Study Group].
Akaza H; Shimazaki J; Tashiro K; Kotake T; Okajima E; Kagawa S; Machida T
Gan To Kagaku Ryoho; 1999 Nov; 26(13):2049-53. PubMed ID: 10584570
[TBL] [Abstract][Full Text] [Related]
6. [Menogaril (TUT-7) late phase II study for malignant lymphoma, adult T-cell leukemia and lymphoma (ATLL)].
Taguchi T; Ohta K; Hotta T; Shirakawa S; Masaoka T; Kimura I
Gan To Kagaku Ryoho; 1997 Aug; 24(10):1263-71. PubMed ID: 9279345
[TBL] [Abstract][Full Text] [Related]
7. Protection from carcinogen-induced murine bladder carcinoma by interferons and an oral interferon-inducing pyrimidinone, bropirimine.
Borden EC; Sidky YA; Ertürk E; Wierenga W; Bryan GT
Cancer Res; 1990 Feb; 50(4):1071-4. PubMed ID: 2297754
[TBL] [Abstract][Full Text] [Related]
8. [Late phase II clinical study of amrubicin hydrochloride, a novel synthetic anthracycline derivative anticancer agent, for malignant lymphoma].
Akutsu M; Kano Y; Ogawa M; Miura A; Hirano M; Masaoka T; Tatsumi N
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1867-76. PubMed ID: 11729479
[TBL] [Abstract][Full Text] [Related]
9. [Early phase II clinical trial of amrubicin hydrochloride in patients with malignant lymphoma].
Masaoka T; Ogawa M; Inoue K; Sanpi K; Kuraishi Y; Toki H; Tamura K; Takagi T; Shibata A; Hirano M; Ezaki K; Shirakawa S; Matsuda T; Kimura I
Gan To Kagaku Ryoho; 2001 Nov; 28(12):1857-65. PubMed ID: 11729478
[TBL] [Abstract][Full Text] [Related]
10. Bropirimine, an orally active anticancer agent for superficial bladder cancer.
Akaza H; Kotake T; Machida T
Eur Urol; 1998 Aug; 34(2):107-10. PubMed ID: 9693244
[TBL] [Abstract][Full Text] [Related]
11. [Clinical efficacy of recombinant human leukocyte A interferon (rIFN-alpha A) on malignant tumors of the urogenital tract].
Gan To Kagaku Ryoho; 1985 Apr; 12(4):921-7. PubMed ID: 3885863
[TBL] [Abstract][Full Text] [Related]
12. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for cervical cancer of the uterus].
Noda K; Ikeda M; Yakushiji M; Nishimura H; Terashima Y; Sasaki H; Hata T; Kuramoto H; Tanaka K; Takahashi T
Gan To Kagaku Ryoho; 1992 Jun; 19(6):885-92. PubMed ID: 1605666
[TBL] [Abstract][Full Text] [Related]
13. [Phase II study of UFT for malignant tumors of urinary organs].
Shida K; Yamanaka H; Ito Y; Shimazaki J; Isaka S; Yokokawa M; Fukui I; Kawai H; Akimoto M; Yoshida K
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1307-14. PubMed ID: 6428325
[TBL] [Abstract][Full Text] [Related]
14. [In vitro direct antiproliferative activity and in vivo antitumor activity of bropirimine against bladder cancer].
Tahara M; Nomura S; Takahashi M; Takagi H; Hashimoto M; Eto H; Kamidono S
Gan To Kagaku Ryoho; 1996 Jul; 23(8):1039-44. PubMed ID: 8687218
[TBL] [Abstract][Full Text] [Related]
15. [Clinical efficacy of GG032X tablets, a new dosage form of ondansetron (fast dispersing tablet), on cisplatin-induced nausea and emesis].
Ariyoshi Y; Nukariya N; Akasaka Y; Suminaga M; Ota J; Ikeda M; Taguchi T
Gan To Kagaku Ryoho; 1997 Jun; 24(8):995-1011. PubMed ID: 9212810
[TBL] [Abstract][Full Text] [Related]
16. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
Hurwitz HI; Cohen RB; McGovren JP; Hirawat S; Petros WP; Natsumeda Y; Yoshinari T
Cancer Chemother Pharmacol; 2007 Jan; 59(1):139-47. PubMed ID: 16819636
[TBL] [Abstract][Full Text] [Related]
17. [A phase II clinical study of cis-diammine glycolato platinum, 254-S, for gastrointestinal cancers. 254-S Gastrointestinal Cancer Study Group].
Taguchi T; Wakui A; Nabeya K; Kurihara M; Isono K; Kakegawa T; Ota K
Gan To Kagaku Ryoho; 1992 Apr; 19(4):483-8. PubMed ID: 1558398
[TBL] [Abstract][Full Text] [Related]
18. [Phase II collaborative study of (2''R)-4'-0-tetrahydropyranyladriamycin (THP) for urological malignancies--Urological Co-operative THP Study Group].
Niijima T; Koyanagi T; Sakashita S; Origasa S; Akaza H; Machida T; Koiso K; Rinsho K; Aso Y; Suzuki K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):224-31. PubMed ID: 3947104
[TBL] [Abstract][Full Text] [Related]
19. [Phase II study of cisplatin in esophageal carcinoma].
Nishihira T; Abo S; Mori S; Isono K; Endo M; Iizuka T; Fujimaki M; Sugimachi K; Kakegawa T; Kasai M
Gan To Kagaku Ryoho; 1986 Oct; 13(10):2939-46. PubMed ID: 3767386
[TBL] [Abstract][Full Text] [Related]
20. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
